UBS raised the firm’s price target on Guardant Health (GH) to $175 from $110 and keeps a Buy rating on the shares. Guardant Health’s strong growth drivers, FDA milestones, and Medicare reimbursement opportunities position it uniquely in diagnostics, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $135 from $115 at Guggenheim
- Guardant Health, Jabil, NeoGenomics, Darden, Cormedix Insider Moves
- Leerink sees Court ruling as small win for Guardant, no change to patent risk
- Guardant Health receives FDA approval for Guardant360 CDx in colorectal cancer
- Guardant Health announces multi-year strategic agreement with Merck